KYBORA and ACA Pharma Partner to Accelerate Access to China’s Life Sciences Market 

Strategic collaboration combines KYBORA’s global biopharma network with ACA Pharma’s 30–90 day Macau registration model to expedite access for rare disease and pediatric therapies in China. 

KYBORA and ACA Pharma announced a strategic partnership that combines ACA Pharma’s innovative 30–90 day market-entry strategy via Macau with KYBORA’s deep network and dealmaking expertise across the global biopharma industry.  

Through this collaboration, KYBORA will work with ACA Pharma to introduce its fast-track registration and commercialization platform to biopharma companies worldwide, transforming how novel therapies enter the Chinese market, particularly in rare diseases, pediatrics, and other high unmet need areas. 

Why this partnership matters 

• Faster market entry: ACA Pharma’s Macau pathway enables regulatory approval in 30–90 days, with direct access to top-tier hospitals in the Greater Bay Area (GBA), serving 120M+ residents. 
• Joint Procurement Network for Pediatric and Orphan Drugs: Based on its successful model with Deflazacort (DEFAL®), ACA Pharma has established a joint procurement network spanning 45 top pediatric hospitals and hematology centers across China, covering over 95% of pediatric and hematology patients nationwide. This network enables streamlined group import licensing through the NMPA, bypassing the need for national registration or local clinical trials, allowing overseas pediatric orphan drugs to reach high-need patients rapidly and compliantly. 
• Zero upfront investment for originators: Originators retain full IP and incur no upfront costs—ACA covers regulatory, logistics, and commercializationint GBA, then China and Southeast Asia. 
• Dealmaking at scale: KYBORA identifies and qualifies global innovators, matching them with ACA’s entry platform. 

“With decades of global dealmaking experience, we’ve seen firsthand how ACA Pharma’s Macau fast-track platform offers the speed and operational rigor innovators need to responsibly access China. Especially in rare diseases and pediatrics, the ability to activate within 30–90 days without local trials is a game-changer. We’re proud to help more therapies reach patients faster and more efficiently.”
Dr. Jean Chatellier, Partner, EVP and Senior Managing Director at KYBORA. 

How KYBORA accelerates ACA Pharma: 

• Senior-level access: Warm, senior level introductions that convert outreach into qualified conversations with decision makers at innovative biotechs and pharma across the U.S. and Europe. 
• Faster deal velocity: Co hosted intro calls where KYBORA helps frame the Macau fast track model in real time to keep momentum strong. 
• Higher hit rate: Pre qualification of programs aligned to ACA strengths (e.g., rare disease, pediatrics), to raise conversion. 
• Amplified awareness: Joint outreach and coordinated announcements highlighting ACA’s 30–90 day Macau entry pathway. 

“KYBORA is a high-impact partner, opening doors and accelerating execution. Through senior-level introductions and real-time framing, they help us activate our Macau pathway faster and with greater fit. Together, we’re enabling direct access to top-tier hospitals and delivering life-changing therapies to patients across Asia.”
Mike Zhou, Chief Executive Officer at ACA Pharma. 

Contact: To explore how this partnership may support your entry into China or Southeast Asia, please contact KYBORA at jean@kybora.com. KYBORA and ACA will jointly assess opportunities with interested companies. 

About KYBORA

KYBORA is a global advisory firm and investment bank whose mission is to guide transformative healthcare companies to enduring success globally. We provide M&A, licensing, fundraising, and strategic advisory services to the global healthcare  industry, creating value for our clients worldwide. With offices in the US, Switzerland, and China, and a direct presence in all key healthcare  markets around the world, KYBORA offers unparalleled global reach and local knowledge. Contact us to explore how we can help you address your most pressing challenges. Learn more at www.kybora.com.

About ACA Pharma 

U.S.-based ACA Pharma is a trusted partner in biopharma commercialization across Greater China and Southeast Asia, providing regulatory, market access, and distribution capabilities Learn more at www.acapharma.net.